new fda ruling on tirzepatide Compounders lose battle over Eli Lilly weight loss drug and shortage list FDA Announces End To Compounded

GLP-1 receptor agonists in idiopathic intracranial hypertension

Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease

weight loss) , the documentation your provider submits , whether your plan includes weight-loss drug benefits , and how the medication is positioned on your plans formulary

any off-label combination requires close specialist supervision with regular monitoring

The Conclusion The study concluded that patients with obesity-related heart failure (HFpEF) and Type 2 diabetes who took semaglutide experienced larger reductions in heart failure-related symptoms, greater weight loss and physical limitations than the placebo in one year